 |
|
Imatinib mesylate-induced interstitial lung disease in a patient with prior history of Mycobacterium tuberculosis infection
Na-Ri Lee, Ji Won Jang, Hee Sun Kim, Ho-Young Yhim
Korean J Intern Med. 2015;30(4):550-553. Published online 2015 Jun 29 DOI: https://doi.org/10.3904/kjim.2015.30.4.550
|
|
Citations to this article as recorded by
 Hypersensitivity pneumonitis related to imatinib mesylate therapy in a patient with chronic myeloid leukemia
Faten Kallel, Olfa Kassar, Imen Maaloul, Maha Charfi, Kamilia Ksouda, Moez Elloumi
Journal of Oncology Pharmacy Practice.2021; 27(7): 1762. CrossRef Effects of host‐directed therapies on the pathology of tuberculosis
Liana Tsenova, Amit Singhal
The Journal of Pathology.2020; 250(5): 636. CrossRef Imatinib-induced irreversible interstitial lung disease
Ping Zhang, Jingfeng Huang, Fangfang Jin, Jiaohai Pan, Guifang Ouyang
Medicine.2019; 98(8): e14402. CrossRef Update on the management of chronic myeloid leukemia: current best practice and future directions
Aisling Nee, Jeffrey H. Lipton
Expert Opinion on Orphan Drugs.2019; 7(4): 157. CrossRef Association between infection and severe drug adverse reactions: an analysis using data from the Japanese Adverse Drug Event Report database
Takuya Imatoh, Kimie Sai, Chisato Fukazawa, Yasushi Hinomura, Ryosuke Nakamura, Yoshimi Okamoto-Uchida, Katsunori Segawa, Yoshiro Saito
European Journal of Clinical Pharmacology.2017; 73(12): 1643. CrossRef Imatinib
Reactions Weekly.2015; 1564(1): 104. CrossRef
|